Latest News

  • DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, is pleased to announce today that the U.S. Food and Drug Administration (“FDA”) has granted orphan...
  • ST. LOUIS, Dec. 15, 2020 /PRNewswire/ — Centene Corporation (NYSE: CNC) today announced it has signed a definitive agreement to acquire PANTHERx, one of the largest and fastest-growing specialty pharmacies in the United States specializing in orphan drugs and rare diseases. The transaction is subject to regulatory approvals and is expected to close by the end of...
  • At the start of the year, pharmacy benefit manager OptumRx predicted that 40% of all new FDA-approved products in 2020 would be orphan drugs. The PBM hasn’t changed that forecast, but it has come out with a bold new prediction about drugs that address small patient populations. Developers of orphan...


Rare disease spotlight


We need your help to build a GLOBAL CHAIN OF LIGHTS 💫 illuminating emblematic buildings all around the world for #RareDiseaseDay!

Do you want to contribute? 👀

🕌 Follow these guidelines!

In today's #DecodingDravet blog @Science_Hood discusses what to consider before sharing too many personal details on #socialmedia while in an active #clinicaltrial

Last day to register for #RareAcrossAmerica2021

Start the year by making an impact on federal policy close to your home. Share your rare disease story and meet other rare disease advocates!

To register visit:

Join us Tuesday, February 9th at 6:30pm EST for the HAEA Webinar: 2021 Legislative Update and Welcome to Congress!

Register here:

#HAEA #HereditaryAngioedema #HAE #Advocacy #HMCW #Webinar

Load More...